Data released May 9 by the Alliance for Regenerative Medicine (ARM) illustrates the growth of clinical activity where gene therapy is concerned.
ARM’s Quarterly Regenerative Medicine Global Data Report for the first quarter of 2019 showed 372 gene therapy clinical trials were in progress as of the end of Q1. Interestingly, a majority (217 or 58%) were studies in Phase II, followed by Phase I (123 or 33%), and Phase III (32 or 9%).
The number of gene therapy clinical trials inched up by 10 from the 362 recorded as of the end of 2018. More significantly, the number of clinical studies jumped 17% year-over-year from the 319 trials in progress as of the first three months of 2018.
